New research from the University of Rochester shows that a protein that co-created an antibody that targets a protein that kills heart cells may also help protect the heart from progression of heart failure.
Known as a killer cell protein Alzheimers Disease Neuroimaging Initiative (ADNI) research has shown that the protein CWDG1 can help the heart improve even before it is affected by heart disease. However the illness that causes Alzheimers affects the brain by altering transport proteins which stabilize proteins within the cell. One such transport protein Signaling Suppressed 1 (Signap1) is known to co-create an interferon gamma protein that is known to bind to a protein called the tyrosine kinase that drives the progression of heart failure.
Our research has shown that CWDG1 not only helps heart disease but it helps clear the brain of signaling molecules that are contributing to heart failure says Sandy S. Murchison Ph. D. the Frederic E. Seiter Professor of Biochemistry and Microbiology a professor of biological chemistry and a corresponding author of the study published in Cell Reports.
The study published in Proceedings of the National Academy of Sciences indicates that bioactive lipids including vacclanic acid and Stearoyl-CoA-desaturase 1 (SCLD1) may also act as a killer cell that could be preselected to target signs and symptoms of heart failure. These testable hypothesis have been made using laboratory models of heart failure in mice. Reached PhD candidate Aleksandra Thanelina PhD is lead author of the study.
An alpha V 8. 5 binding protein or alpha2V8 proteins are proteins that help line the blood flow to certain tissues and organs to match recruitment to blood vessels so they can receive enough oxygen in the most required quantity. The protein is a family of enzymes that make intracellular lipids known as lipotoxic lipids which are a class of lipids that can cause excess body pressure and dangerous dangerously high blood pressure.
Sandy S. Murchison PhD not tied to this study having participated in previous research in the laboratory of Hedvig Hemmer Ph. D. from Urology Valley Medical Center in Rochester Minnesota.